← Leaderboards
Darrell J Triulzi
University Of Pittsburgh At Pittsburgh
$6,789,583
Attributed
$10,988,036
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,988,036 · 6
By mechanism
UH3$6,343,534 · 1
U01$2,019,185 · 1
UG3$1,459,550 · 1
R34$593,822 · 1
N01$553,625 · 1
M01$18,320 · 1
Top collaborators
- Mark Thomas Gladwin4 shared
- Jason Lee Sperry3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Akira Sekikawa$16,215,016
- Henry E Wang$15,583,055
- Maria Mori Brooks$44,871,550
- Robert S. Clark$12,893,742
- Masashi Okubo$976,790
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsBloodHospitalsTransfusionClinical ResearchAdultSafetyStandard Of CareProtocols DocumentationOrganPlasmaPreventCessation Of LifeMorbidity - Disease RateMortalityTherapeutic InterventionAccident And Emergency DepartmentErythrocytesAcuteHealthcareFunctional DisorderOperative Surgical ProceduresResourcesHemostatic Agents
Grant awards (18)
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$680,622
UH3 · FY2022 · HL
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$2,887,088
UH3 · FY2021 · HL
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$2,775,824
UH3 · FY2020 · HL
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)$1,459,550
UG3 · FY2019 · HL
Pragmatic, Prehospital Group O Whole Blood Early Resuscitation Pilot Trial$197,845
R34 · FY2019 · HL
Pragmatic, Prehospital Group O Whole Blood Early Resuscitation Pilot Trial$197,759
R34 · FY2018 · HL
Pragmatic, Prehospital Group O Whole Blood Early Resuscitation Pilot Trial$198,218
R34 · FY2017 · HL
Transfusion Medicine/Hemostasis Clinical Research Network$162,422
U01 · FY2012 · HL · contact PI
Retrovirus Epidemiology Donor Study-II (REDS-II) Blood Center$383,135
N01 · FY2010 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Network$185,625
U01 · FY2009 · HL · contact PI
Retrovirus Epidemiology Donor Study-II (REDS-II) Blood Center$170,490
N01 · FY2009 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Network$185,625
U01 · FY2007 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Netwo*$292,939
U01 · FY2006 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Netwo*$299,820
U01 · FY2005 · HL
DETERM OPTIMAL PROPHYLACTIC PLATLET STRATEGY PREVNT BLEED'G THROMBOCYTOPERIC$18,320
M01 · FY2005 · RR
Transfusion Medicine/Hemostasis Clinical Research Netwo*$298,109
U01 · FY2004 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$294,705
U01 · FY2003 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$299,940
U01 · FY2002 · HL